Sort by
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Drug Treatment
100%
Receptor Agonist
100%
A1 Receptor
100%
Glucagon-like
100%
Meta-analysis of Randomized Controlled Trials
100%
Network Meta-analysis
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
87%
Finerenone
75%
Tirzepatide
62%
Admission to Hospital
37%
End-stage Kidney Disease
37%
Heart Failure
25%
Randomized Controlled Trial
25%
Drug Class
25%
Cardiovascular Mortality
25%
Mineralocorticoid Receptor Antagonists
25%
Kidney Outcomes
25%
Odds Ratio
12%
Confidence Interval
12%
Quality of Life
12%
MEDLINE
12%
Treatment Options
12%
Subgroup Analysis
12%
Diabetes
12%
Embase
12%
All-cause Mortality
12%
Clinical Practice Guidelines
12%
Cardiovascular Outcomes
12%
Nonfatal Stroke
12%
Chronic Kidney Disease
12%
Gastrointestinal Side Effects
12%
Adverse Cardiovascular Events
12%
Continuous Assessment
12%
Assessment Development
12%
Absolute Benefit
12%
Ovid
12%
Cochrane
12%
Large Reduction
12%
Hyperkalemia
12%
Baseline Risk
12%
Reducing End
12%
Assessment Approach
12%
Development Approach
12%
Grading of Recommendations
12%
Evaluation Assessment
12%
Nonfatal Myocardial Infarction
12%
Basal Insulin
12%
Evaluation Approach
12%
Certainty of Evidence
12%
Recommendation Approach
12%
Non-English Language
12%
Controlled English
12%
English Language Studies
12%
Thiazolidinediones
12%
Comparison with a Standard
12%
Genital Infection
12%
Glucose-dependent Insulinotropic Polypeptide
12%
Treatment Class
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Randomized Controlled Trial
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Maturity Onset Diabetes of the Young
100%
sodium glucose cotransporter-2 inhibitors
87%
Finerenone
75%
Tirzepatide
62%
End Stage Renal Disease
37%
Congestive Heart Failure
25%
Mineralocorticoid Antagonist
25%
Adverse Event
12%
Heart Infarction
12%
Chronic Kidney Failure
12%
Hyperkalemia
12%
Cerebrovascular Accident
12%
Gastric Inhibitory Polypeptide
12%
Thiazolidinedione
12%
Genital Tract Infection
12%